Neurocrine Biosciences | NBIX - الربح الإجمالي على المبيعات

سعر السهم
127.68
التغيير اليومي
-2.02 -1.56%
شهريا
-0.55%
سنويا
14.08%
Q1 التوقعات
123.85




الربح الإجمالي على المبيعات تغيير تاريخ
AbbVie USD 10.47B 605M 2025-09
Acadia Pharmaceuticals USD 257.76M 778K 2025-12
Agios Pharmaceuticals USD 18.09M 6.89M 2025-12
ALKERMES USD 338.34M 72.51M 2025-12
Alnylam Pharmaceuticals USD 829.31M 219.56M 2025-12
Amgen USD 6.48B 307M 2025-09
Biogen USD 1.65B 34.6M 2025-12
BioMarin Pharmaceutical USD 713.01M 81.81M 2025-12
Cytokinetics USD 17.76M 15.82M 2025-12
Enanta Pharmaceuticals -22.29M 23.75M 2024-12
Exelixis USD 572.18M 7M 2025-12
Gilead Sciences USD 6.31B 106M 2025-12
Halozyme Therapeutics USD 281.77M 2.41M 2025-09
Incyte USD 1.39B 118.68M 2025-12
Ionis Pharmaceuticals USD 195M 40M 2025-12
Nektar Therapeutics USD 13.75M 650K 2024-06
Neurocrine Biosciences USD 787.9M 7M 2025-12
Pfizer USD 3.54B 7.61B 2025-09
Prothena USD 21K 2.39M 2025-12
Regeneron Pharmaceuticals USD 3.3B 67M 2025-12
Repligen USD 103.83M 3.32M 2025-12
Rigel Pharmaceuticals USD 28.49M 7.01M 2024-06
Sarepta Therapeutics USD 43.55M 204.36M 2025-12
Teva Pharmaceutical Industries USD 2.66B 351M 2025-12
Ultragenyx Pharmaceutical USD 178M 46.06M 2025-12
Vertex Pharmaceuticals USD 2.72B 62.4M 2025-12
Xoma 992K 846K 2024-06